La homocisteína y la enfermedad cardiovascular
ABSTRACT: Homocysteine is a no essential sulfured aminoacid, that contains a thiol group in its structure. The homocysteine is produced in almost all human tissues for the methionine metabolism. In 1990, The Framingham study, demostrated that homocysteine (Hcy) could be a possible risk factor for ca...
- Autores:
-
Ruiz P., Adriana Marcela
Laverde G., Diana Patricia
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2006
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- spa
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/11388
- Acceso en línea:
- http://hdl.handle.net/10495/11388
- Palabra clave:
- Homocisteína
Homocysteine
Hiperhomocisteinemia
Hyperhomocysteinemia
Factores de riesgo
Risk factors
Enfermedad cardiovascular
Cardiovascular disease
- Rights
- openAccess
- License
- Atribución-NoComercial-CompartirIgual 2.5 Colombia (CC BY-NC-SA 2.5 CO)
id |
UDEA2_ccb86922029297644345a7f471c8d1f2 |
---|---|
oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/11388 |
network_acronym_str |
UDEA2 |
network_name_str |
Repositorio UdeA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
La homocisteína y la enfermedad cardiovascular |
dc.title.alternative.spa.fl_str_mv |
Homocysteine and cardiovascular disease |
title |
La homocisteína y la enfermedad cardiovascular |
spellingShingle |
La homocisteína y la enfermedad cardiovascular Homocisteína Homocysteine Hiperhomocisteinemia Hyperhomocysteinemia Factores de riesgo Risk factors Enfermedad cardiovascular Cardiovascular disease |
title_short |
La homocisteína y la enfermedad cardiovascular |
title_full |
La homocisteína y la enfermedad cardiovascular |
title_fullStr |
La homocisteína y la enfermedad cardiovascular |
title_full_unstemmed |
La homocisteína y la enfermedad cardiovascular |
title_sort |
La homocisteína y la enfermedad cardiovascular |
dc.creator.fl_str_mv |
Ruiz P., Adriana Marcela Laverde G., Diana Patricia |
dc.contributor.author.none.fl_str_mv |
Ruiz P., Adriana Marcela Laverde G., Diana Patricia |
dc.subject.none.fl_str_mv |
Homocisteína Homocysteine Hiperhomocisteinemia Hyperhomocysteinemia Factores de riesgo Risk factors Enfermedad cardiovascular Cardiovascular disease |
topic |
Homocisteína Homocysteine Hiperhomocisteinemia Hyperhomocysteinemia Factores de riesgo Risk factors Enfermedad cardiovascular Cardiovascular disease |
description |
ABSTRACT: Homocysteine is a no essential sulfured aminoacid, that contains a thiol group in its structure. The homocysteine is produced in almost all human tissues for the methionine metabolism. In 1990, The Framingham study, demostrated that homocysteine (Hcy) could be a possible risk factor for cardiovascular disease. Since 2003 Hcy has been considered an “emergent” risk factor. The hiperhomocysteinemia is defined when plasmatic levels of total Hcy is above of 15 μmol/L. It`s classified according to three severity stages, moderate 15-30 μmol/L, intermediate 31-100 μmol/L and severe, higher than 100 μmol/L. Hiperhomocysteinemia can be produced by enzymatic deficiency in any of its metabolic routes, and also due to low plasmatic levels of folic acid, vitamins B6 or B12 and renal failure, because kidney is the main organ to eliminate the Hcy from plasma. Folic acid diet supplementation could reduce Hcy blood concentration about 25%, and supplementation with vitamin B12 about 7%, however the supplementation with vitamin B6 has not shown any effect. Healthy life style, quit smoking, and balanced diet with a moderate consumption of coffee and alcohol may reduce Hcy plasmatic levels. |
publishDate |
2006 |
dc.date.issued.none.fl_str_mv |
2006 |
dc.date.accessioned.none.fl_str_mv |
2019-07-09T15:37:50Z |
dc.date.available.none.fl_str_mv |
2019-07-09T15:37:50Z |
dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
dc.type.local.spa.fl_str_mv |
Artículo de investigación |
format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
status_str |
publishedVersion |
dc.identifier.citation.spa.fl_str_mv |
Ruiz AM, Laverde DP. La homocisteína y la enfermedad cardiovascular. Perspect. Nutr. Humana.. 2006;16:53-66. |
dc.identifier.issn.none.fl_str_mv |
0124-4108 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10495/11388 |
dc.identifier.eissn.none.fl_str_mv |
2248-454X |
identifier_str_mv |
Ruiz AM, Laverde DP. La homocisteína y la enfermedad cardiovascular. Perspect. Nutr. Humana.. 2006;16:53-66. 0124-4108 2248-454X |
url |
http://hdl.handle.net/10495/11388 |
dc.language.iso.spa.fl_str_mv |
spa |
language |
spa |
dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Perspect. Nutr. Humana. |
dc.rights.*.fl_str_mv |
Atribución-NoComercial-CompartirIgual 2.5 Colombia (CC BY-NC-SA 2.5 CO) |
dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.*.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/co/ |
dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
rights_invalid_str_mv |
Atribución-NoComercial-CompartirIgual 2.5 Colombia (CC BY-NC-SA 2.5 CO) https://creativecommons.org/licenses/by-nc-sa/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-sa/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Universidad de Antioquia, Escuela de Nutrición y Dietética |
dc.publisher.place.spa.fl_str_mv |
Medellín, Colombia |
institution |
Universidad de Antioquia |
bitstream.url.fl_str_mv |
http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/2/license_url http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/3/license_text http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/4/license_rdf http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/5/license.txt http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/1/RuizAdriana_2006_HomocisteinaEnfermedadCardiovascular.pdf.pdf |
bitstream.checksum.fl_str_mv |
4afdbb8c545fd630ea7db775da747b2f d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e 8a4605be74aa9ea9d79846c1fba20a33 68e159330ae26f1c29f20aa50c784c77 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
_version_ |
1812173099383128064 |
spelling |
Ruiz P., Adriana MarcelaLaverde G., Diana Patricia2019-07-09T15:37:50Z2019-07-09T15:37:50Z2006Ruiz AM, Laverde DP. La homocisteína y la enfermedad cardiovascular. Perspect. Nutr. Humana.. 2006;16:53-66.0124-4108http://hdl.handle.net/10495/113882248-454XABSTRACT: Homocysteine is a no essential sulfured aminoacid, that contains a thiol group in its structure. The homocysteine is produced in almost all human tissues for the methionine metabolism. In 1990, The Framingham study, demostrated that homocysteine (Hcy) could be a possible risk factor for cardiovascular disease. Since 2003 Hcy has been considered an “emergent” risk factor. The hiperhomocysteinemia is defined when plasmatic levels of total Hcy is above of 15 μmol/L. It`s classified according to three severity stages, moderate 15-30 μmol/L, intermediate 31-100 μmol/L and severe, higher than 100 μmol/L. Hiperhomocysteinemia can be produced by enzymatic deficiency in any of its metabolic routes, and also due to low plasmatic levels of folic acid, vitamins B6 or B12 and renal failure, because kidney is the main organ to eliminate the Hcy from plasma. Folic acid diet supplementation could reduce Hcy blood concentration about 25%, and supplementation with vitamin B12 about 7%, however the supplementation with vitamin B6 has not shown any effect. Healthy life style, quit smoking, and balanced diet with a moderate consumption of coffee and alcohol may reduce Hcy plasmatic levels.RESUMEN: La homocisteína es un aminoácido sulfurado no esencial, que contiene un grupo tiol y se genera en casi todos los tejidos humanos, como producto del metabolismo de la metionina. Desde el año 1990, el estudio de Framingham reconoció la homocisteína (Hcy) como un posible factor de riesgo para enfermedad cardiovascular (ECV) y en el año 2003 lo declaró como factor de riesgo “emergente”. La hiperhomocisteinemia se define como el aumento de los niveles plasmáticos de Hcy total (unida a proteínas más fracción libre), por encima de 15 μmol/L y se clasifica en tres niveles de severidad, moderado de 15-30 μmol/L, intermedio de 31-100 μmol/L y severo mayor de 100 μmol/L. La hiperhomocisteinemia puede producirse por una deficiencia enzimática en alguno de los pasos de su metabolismo, también se puede presentar por bajos niveles plasmáticos del ácido fólico y las vitaminas B6 y/o B12. La insuficiencia renal puede ser otra causa, debido a que el riñón es la ruta para eliminar la Hcy del plasma. La suplementación dietaria con ácido fólico reduce las concentraciones de Hcy en sangre en un 25%, la suplementación con vitamina B12 en un 7%, mientras que la suplementación con vitamina B6 no tiene efecto en esta disminución. Un estilo de vida saludable, una dieta balanceada con un moderado consumo de café y alcohol y dejar de fumar, contribuye en la reducción de los niveles plasmáticos de Hcy.application/pdfspaUniversidad de Antioquia, Escuela de Nutrición y DietéticaMedellín, Colombiainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTArtículo de investigaciónhttp://purl.org/coar/version/c_970fb48d4fbd8a85Atribución-NoComercial-CompartirIgual 2.5 Colombia (CC BY-NC-SA 2.5 CO)info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-sa/4.0/HomocisteínaHomocysteineHiperhomocisteinemiaHyperhomocysteinemiaFactores de riesgoRisk factorsEnfermedad cardiovascularCardiovascular diseaseLa homocisteína y la enfermedad cardiovascularHomocysteine and cardiovascular diseasePerspect. Nutr. Humana.Perspectivas en Nutrición Humana536616CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/2/license_url4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/3/license_textd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfLicenciaapplication/rdf+xml; charset=utf-80http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/4/license_rdfd41d8cd98f00b204e9800998ecf8427eMD54LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/5/license.txt8a4605be74aa9ea9d79846c1fba20a33MD55ORIGINALRuizAdriana_2006_HomocisteinaEnfermedadCardiovascular.pdf.pdfRuizAdriana_2006_HomocisteinaEnfermedadCardiovascular.pdf.pdfArtículo de Revistaapplication/pdf261031http://bibliotecadigital.udea.edu.co/bitstream/10495/11388/1/RuizAdriana_2006_HomocisteinaEnfermedadCardiovascular.pdf.pdf68e159330ae26f1c29f20aa50c784c77MD5110495/11388oai:bibliotecadigital.udea.edu.co:10495/113882021-10-25 13:37:37.831Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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 |